Pitobrutinib efficacy and effects

Pirtobrutinib (Pirtobrutinib), trade name Jaypirca, is a non-covalent (reversible) brutinib-sensitive kinase (BTK) inhibitor developed by Lilly of the United States. This innovative drug is mainly used to treat adult patients with mantle cell lymphoma (MCL) who have relapsed or been refractory after at least two systemic therapies, including BTK inhibitors. In addition, a new indication of pitobrutinib was approved by the U.S. Food and Drug Administration (FDA) for the treatment of adult patients with chronic lymphocytic leukemia or small lymphocytic lymphoma (CLL/SLL) who have received at least two prior therapies, including a BTK inhibitor and a BCL-2 inhibitor.

The main effect of Pitobrutinib lies in its ability to precisely act on BTK, a key molecule in the B cell receptor signaling pathway. By inhibiting abnormal activities in this signaling pathway, it blocks the growth and division of lymphoma cells. This specific mechanism of action allows pitobrutinib to exhibit significant efficacy in the treatment of specific types of lymphoma. Clinical trials have shown that when pittobrutinib is used to treat relapsed or refractory mantle cell lymphoma (MCL), the objective response rate (ORR) reaches 50%, and the complete response rate (CR) is 13%. In trials for chronic lymphocytic leukemia or small lymphocytic lymphoma (CLL/SLL), the overall response rate (ORR) of pitobrutinib was as high as 72%.

The effect of pitobrutinib is not only limited to its significant anti-tumor activity, but also reflected in its relatively good safety and tolerability. Compared with traditional chemotherapy drugs, pitobrutinib has fewer side effects and higher clinical safety. Although some adverse reactions, such as infection, bleeding, and neutropenia, may occur during treatment, these side effects are usually controllable, and most patients are able to tolerate and complete the treatment regimen. In addition, the use of pitobrutinib also reduces the impact on normal cells, helping to reduce the incidence of adverse reactions during treatment.

Pittobrutinib, as a new type of targeted therapy, brings a new treatment option to patients with B-cell lymphoma. Its emergence not only improves the quality of life of patients, but also brings new hope to the field of lymphoma treatment. With the in-depth understanding of its mechanism of action and the expansion of clinical applications, pitobrutinib is expected to become one of the important drugs in the treatment of lymphoma in the future, providing patients with more effective treatment options.

At this stage, Pitobrutinib is not yet on the market in China. If patients need this drug, they may consider purchasing it abroad or contacting a formal overseas medical consulting company. It is reported that pitobrutinib is divided into two types: original drugs and generic drugs in overseas markets. Taking the original drug marketed in the United States as an example, the price of 50mg*30 tablets is about 100,000 yuan, while the price of generic drugs in Laos is about 4,500 yuan. If you need to learn more about pitobrutinib, please consult a regular overseas consulting company.

xa0

Reference: https://www.nejm.org/doi/full/10.1056/NEJMoa2300696